Precigen company information, Employees & Contact Information

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis PR Newswire

83% of Complete Responders Ongoing at 36 Months — Precigen's PAPZIMEOS Shows Durable Responses Stock Titan

Precigen Announces Up to $125 Million Non-Dilutive Financing Investing News Network

Precigen Announces Up to $125 Million Non-Dilutive Financing Financial Times

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright PR Newswire

First-Ever FDA Approved Therapy: Precigen Leadership to Detail Breakthrough RRP Treatment at Key Events Stock Titan

FDA Approves Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy Papzimeos CGTLive®

$125M Non-Dilutive Deal: Precigen Secures Major Funding for Revolutionary HPV Immunotherapy Launch Stock Titan

Precigen to Participate in the Stifel 2024 Healthcare Conference PR Newswire

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch PR Newswire

Precigen Reports First Quarter 2025 Financial Results and Business Updates PR Newswire

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis PR Newswire

Precigen Reports Full Year 2024 Financial Results and Business Updates PR Newswire

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 PR Newswire

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock PR Newswire

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting PR Newswire

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock PR Newswire

Papzimeos Approved for Recurrent Respiratory Papillomatosis Infectious Disease Advisor

Precigen Announces Up to $125 Million Non-Dilutive Financing citybiz

FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review CGTLive®

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th PR Newswire

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® PR Newswire

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics PR Newswire

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval PR Newswire

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis PR Newswire

Precigen Completes Series Of Transactions To Solidify Healthcare Focus PR Newswire

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients PR Newswire

Precigen Appoints Phil Tennant as Chief Commercial Officer citybiz

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers PR Newswire

FDA approves papzimeos for adults with recurrent respiratory papillomatosis Medical Xpress

Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics PR Newswire

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients PR Newswire

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes PR Newswire

Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes PR Newswire

Precigen: August Is Pivotal For This Biotech Innovator Seeking Alpha

Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure PR Newswire

Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland PR Newswire

Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer citybiz

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis Stock Titan

URUS to Purchase Trans Ova Genetics Dairy Herd Management

Merck KGaA, Darmstadt, Germany Increases Ownership In Precigen citybiz

IMI Precision Engineering Railway Technology

Hi-Precision Diagnostics: 23 Years of providing hi-quality healthcare for all Inquirer.net

Hi-Precision Diagnostic­s’ 50th Branch Opens in Ayala North Exchange PressReader